Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7913491 | 1.00 | PKM (0.49) | PKMHTTSMN1; SMN2DRD2DRD4 | |
| SCHEMBL14642001 | 1.00 | PKM (0.49) | PKMHTTSMN1; SMN2DRD2DRD4 | |
| SCHEMBL3014720 | 1.00 | PKM (0.49) | PKMHTTSMN1; SMN2DRD2DRD4 | |
| SCHEMBL2999490 | 1.00 | PKM (0.49) | PKMHTTSMN1; SMN2DRD2DRD4 | |
| SCHEMBL2998960 | 0.88 | SIGMAR1 (0.45) | PKMHTTSMN1; SMN2RORC | |
| SCHEMBL7915812 | 0.85 | DRD2 (0.50) | DRD2DRD4 | |
| SCHEMBL3115936 | 0.85 | DRD2 (0.50) | DRD2DRD4 | |
| SCHEMBL7914327 | 0.85 | DRD2 (0.50) | DRD2DRD4 | |
| SCHEMBL3007605 | 0.83 | DRD2 (0.50) | DRD2DRD4RORC | |
| SCHEMBL7911495 | 0.83 | DRD2 (0.50) | DRD2DRD4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391615-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8324248-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRK1, OPRM1, OPRL1 | PKM 584/4885HTT 447/4885SMN1; SMN2 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.